NCT05824468 2026-03-10
Zimberelimab Plus Lenvatinib After Progression on Prior Immune Checkpoint Inhibitors for Advanced Cervical Cancer
Sun Yat-sen University
Phase 2 Active not recruiting
Clinical Trials
17 trialsNCT03891953 2026-01-21
Study of Safety and Efficacy of DKY709 Alone or in Combination With PDR001 in Patients With Advanced Solid Tumors.
Novartis
Phase 1 Active not recruiting
NCT05201066 2026-01-07
Roll-over Study for Patients Who Have Completed a Prior Novartis-sponsored Sabatolimab (MBG453) Study and Are Judged by the Investigator to Benefit From Continued Treatment With Sabatolimab.
Novartis
Phase 2 Active not recruiting
NCT05631899 2025-11-24
CAR-DC Vaccine and ICIs in Local Advanced/Metastatic Solid Tumors
Chinese PLA General Hospital
Phase 1 Active not recruiting
NCT04058756 2025-10-07
Rollover Study for Continued Safety and Tolerability in Subjects Treated With Spartalizumab Alone or in Combination With Other Study Treatments
Novartis
Phase 1 Active not recruiting
NCT04544111 2025-10-07
PDR001 Combination Therapy for Radioiodine-Refractory Thyroid Cancer
Memorial Sloan Kettering Cancer Center
Phase 2 Active not recruiting
NCT03961971 2025-09-10
Trial of Anti-Tim-3 in Combination With Anti-PD-1 and SRS in Recurrent GBM
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 1 Active not recruiting
NCT06547957 2025-08-13
A First-in-Human Study of EOS301984 as Monotherapy or Combination Therapy in Adult Participants With Advanced Solid Tumors
iTeos Therapeutics
Phase 1 Active not recruiting
NCT04028245 2025-08-07
SPARC-1
Columbia University
Phase EARLY_PHASE1 Active not recruiting
NCT05751928 2025-07-08
NEO-MIMAJOR
Biocad
Phase 3 Active not recruiting
NCT05607953 2025-07-04
Pressure Enabled Intrapancreatic Delivery of SD-101 With Checkpoint Blockade for Locally Advanced Pancreatic Adenocarcinoma
TriSalus Life Sciences, Inc.
Phase 1 Active not recruiting
NCT03958383 2025-04-18
IT-hu14.18-IL2 With Radiation, Nivolumab and Ipilimumab for Melanoma
University of Wisconsin, Madison
Phase 1/2 Active not recruiting
NCT03860272 2025-02-06
Fc-Engineered Anti-CTLA-4 Monoclonal Antibody in Advanced Cancer
Agenus Inc.
Phase 1 Active not recruiting
NCT05662397 2025-02-04
A Study of HST-1011 Given as Monotherapy and in Combination With an Anti-PD1 Antibody
HotSpot Therapeutics, Inc
Phase 1/2 Active not recruiting
NCT05522582 2024-10-26
Methotrexate Combined With Immunotherapy During Radiotherapy for Solid Tumors
Yancheng First People's Hospital
Phase 2 Active not recruiting
NCT04301557 2024-04-23
PD1 Antibody Toripalimab and Chemoradiotherapy for dMMR/MSI-H Locally Advanced Colorectal Cancer
Sun Yat-sen University
Phase 2 Active not recruiting
NCT04833387 2023-01-11
PD-1 Antibody Following Preoperative Chemoradiotherapy for Locally Advanced pMMR/MSS Rectal Cancer
Sun Yat-sen University
Phase 2 Active not recruiting